Skip to main content
OpenTrials

Clinical trial condition

Respiratory Syncytial Virus Infections

Explore clinical trials studying Respiratory Syncytial Virus Infections. Study availability and eligibility vary by location and protocol.

143 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Respiratory Syncytial Virus Infections trial results

Completed

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

NCT05705440

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Mobile, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Burbank, California, United States
View all 138 locations
View Trial Details
Completed

A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

NCT06083623

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Children's Hospital Capital Institute Pediatrics Beijing, Beijing Municipality, China
  • Jiangjin Central Hospital Chongqing, Chongqing Municipality, China
  • Xiamen maternal and Child Health Hospital Xiamen, Fujian, China
View all 39 locations
View Trial Details
Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

NCT06374394

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Coral Gables, Florida, United States
  • GSK Investigational Site Savannah, Georgia, United States
  • GSK Investigational Site Evansville, Indiana, United States
  • GSK Investigational Site Omaha, Nebraska, United States
View all 24 locations
View Trial Details
Completed

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

NCT06389487

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Glendale, Arizona, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site North Hollywood, California, United States
  • GSK Investigational Site Oakland, California, United States
View all 52 locations
View Trial Details
Completed

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04886596

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Huntsville, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
View all 277 locations
View Trial Details
Completed

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

NCT05879107

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Guntersville, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Huntington Beach, California, United States
  • GSK Investigational Site Modesto, California, United States
View all 38 locations
View Trial Details
Completed

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

NCT02624947

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • Research Site US115 Birmingham, Alabama, United States
  • Research Site US035 Cullman, Alabama, United States
  • Research Site US130 Fort Defiance, Arizona, United States
  • Research Site US123 Phoenix, Arizona, United States
View all 88 locations
View Trial Details

Related conditions